CagriSema

CagriSema is a fixed-dose combination of two separate molecules delivered in one weekly injection: cagrilintide, a long-acting amylin analog, and semaglutide, the familiar GLP-1 agonist. It is investigational in the United States and is not FDA-approved.

Its pivotal obesity trial, REDEFINE 1, randomized 3,417 adults with overweight or obesity across four arms — the combination, semaglutide alone, cagrilintide alone, and placebo. At week 68, estimated mean weight change was −20.4% with cagrilintide-semaglutide versus −3.0% with placebo, a difference of 17.3 percentage points. Participants on the combination were significantly more likely to hit thresholds of 5%, 20%, 25% and even 30% weight loss.

The interesting comparison is internal. Because the trial included semaglutide-alone and cagrilintide-alone arms, it was designed to show what the second molecule adds rather than only beating placebo — a stronger design than most combination trials, and the reason the result carries weight.

The tolerability figure deserves equal attention: gastrointestinal adverse events affected 79.6% of the combination group against 39.9% on placebo, though the trial characterized them as mainly transient and mild to moderate. Eight in ten people reporting nausea, vomiting, diarrhea, constipation or abdominal pain is a high number even when most of it settles.

Two things to keep straight. CagriSema is a co-formulation of two drugs, not a single dual agonist molecule like tirzepatide — a distinction that matters when comparing trial results. And FDA states that cagrilintide cannot be used in compounding under federal law and is not a component of any approved drug, so anything marketed as CagriSema outside a clinical trial is not a legitimate product.

Until approval there is nothing to ask a prescriber except whether a trial is enrolling near you. Our REDEFINE analysis and pipeline tracker follow its progress.